# Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

> **NCT05447494** · PHASE1,PHASE2 · UNKNOWN · sponsor: **CANbridge (Suzhou) Bio-pharma Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Gaucher Disease, Type 1
- Gaucher Disease, Type 3

## Interventions

- **DRUG:** Low-dose CAN103
- **DRUG:** High-dose CAN103

## Key facts

- **NCT ID:** NCT05447494
- **Lead sponsor:** CANbridge (Suzhou) Bio-pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-11
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447494, "Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05447494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*